Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB

Pulmonary Tuberculosis Clinical Trial

— ScreenTB  

Official title:

Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03350048
• Other study ID #: N16/05/070
• Status: Completed
• Start date: April 1, 2016
• Est. completion date: July 31, 2020

Study information

• Verified date: January 2023
• Source: University of Stellenbosch
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB)

Introduction: Tuberculosis (TB) places severe pressure on health care services of the developing world. Despite the introduction of the highly sensitive and specific GeneXpert MTB/RIF (GeneXpert) test [1] with a potential turn-around time of two hours, many people in high TB prevalence areas still do not have access to efficient TB diagnostic services due to logistical constraints in these settings. A cost effective, rapid, point-of-care screening test with high sensitivity would identify people with a high likelihood for active TB and would prioritize them for testing with more expensive, technically or logistically demanding assays including GeneXpert or liquid culture, facilitating cost-effective diagnostic work-up in resource-limited settings. A serum cytokine signature for active TB disease, discovered in the AE-TBC project, with a sensitivity of 89% (CI 78 - 95%) and specificity of 76% (CI 68 - 83%), will be optimised and utilized in a point-of-care format (TransDot) to rapidly test for TB disease in symptomatic people.

Hypothesis: The TransDot test will achieve a sensitivity of > 90% for TB disease, in a training set of people suspected of having TB disease, and be validated (achieve similarly high sensitivity) subsequently in a prospective test set of people suspected of having TB disease, when compared to a composite gold standard of sputum culture, smear, GeneXpert, chest X-ray, TB symptoms and TB treatment response.

Objectives: The overall objective of the study is to incorporate a six-marker serum signature into a multiplex UCP-LFA format, referred to as TransDot, for finger-prick blood testing. The end point of the study is the accuracy (sensitivity and specificity) of the UCP-LFA TransDot test on finger-prick blood for active TB and will be prospectively compared against gold standard composite diagnostic criteria (GeneXpert, MGIT culture, TB sputum smear, CXR, TB symptom screen and response to TB treatment).

Primary: The primary outcome of interest will be accuracy, sensitivity and specificity of the TransDot finger-prick test when compared with the composite gold standard tests.

Description:

Protocol Summary Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB)

Population: A total of 800 people presenting at primary health care clinics with presumed active pulmonary tuberculosis, aged 18 to 70 years, male or female gender, will be recruited. They should be willing to give informed, written consent, including consent for HIV testing. They should have symptoms that could be compatible with active TB (cough > two weeks, plus at least one of the following: fever, weight loss, haemoptysis and night sweats). Participants should not have been on TB treatment for the past 90 days and should not have received immune suppressive therapy, be known with alcohol of drug abuse, have a haemoglobin level <9g/dl or be pregnant or breastfeeding. HIV co-infection is not an exclusion criterion. Participants will be recruited from primary health care clinics in Cape Town, South Africa, Windhoek in Namibia, Addis Ababa in Ethiopia, Banjul in The Gambia and Kampala in Uganda.

Number of Sites: Five sites

Study Duration: 3 years

Subject Duration: 18 months for TB cases, 2 months for non-TB cases

Objectives:

The overall objective of the study is to incorporate a six-marker serum signature into a multiplex UCP-LFA format, referred to as TransDot, for finger-prick blood testing. The end point of the study is the accuracy (sensitivity and specificity) of the UCP-LFA TransDot test on finger-prick blood for active TB and will be prospectively compared against gold standard composite diagnostic criteria (GeneXpert, MGIT culture, TB sputum smear, CXR, TB symptom screen and response to TB treatment).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 969
• Est. completion date: July 31, 2020
• Est. primary completion date: April 30, 2019
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Symptoms suggestive of TB disease: cough for more than two weeks with fever, malaise, weight loss, night sweats, haemoptysis, chest pain or loss of appetite.

• Willingness to give consent to take part in the study.

• Willingness to undergo HIV testing or be willing to have their HIV infection status disclosed to the study field workers.

• Eighteen years or older and aged 70 years or younger.

Exclusion Criteria:

• Permanent residence in study area for less than 3 months or with no permanent address.

• Pregnancy or breastfeeding.

• HB<9g/l

• On TB treatment currently or in the last ninety days.

• HIV positive patients currently on INH prophylaxis, or in the last ninety days.

• Known quinolone or aminoglicozide antibiotic use reported in the past 60 days.

Related Conditions & MeSH terms

• Pulmonary Tuberculosis
• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Diagnostic Test:
• Trans-Dot point-of-care test
Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases. Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response.

Locations

Country	Name	City	State
Ethiopia	Armauer Hansen Research Institute	Addis Ababa
Gambia	Medical Research Council The Gambia	Banjul
Germany	LINQ Management GmbH	Berlin
Germany	European Research and Project Office GmbH	Saarbrücken	Saarland
Namibia	University of Namibia	Windhoek
Netherlands	Leiden University Medical Center (Academisch Ziekenhuis Leiden, LUMC)	Leiden
Netherlands	The European & Developing Countries Clinical Trials Partnership Association (EDCTP)	The Hague	South Holland
South Africa	Stellenbosch University	Cape Town	Western Cape
Uganda	Makerere University	Kampala
United Kingdom	London School of Hygiene and Tropical Medicine	London

Sponsors (8)

Lead Sponsor	Collaborator
Prof Gerhard Walzl	Armauer Hansen Research Institute, Ethiopia, European and Developing Countries Clinical Trials Partnership (EDCTP), Leiden University Medical Center, LINQ Management GMBH, London School of Hygiene and Tropical Medicine, Makerere University, Medical Research Council Unit, The Gambia

Countries where clinical trial is conducted

Ethiopia,  Gambia,  Germany,  Namibia,  Netherlands,  South Africa,  Uganda,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic performance of the TransDot finger-prick test	The primary outcome of interest will be accuracy, sensitivity and specificity of the TransDot finger-prick test when compared with the composite gold standard tests.	3 years
Secondary	POC TransDOT test versus lab-based tests	To evaluate the agreement between the POC TransDot test and laboratory based ELISAs first (both on serum), and subsequently between POC TransDot (on fingerprick blood) and laboratory based TransDot (on serum).	3 years
Secondary	TransDOT as treatment response marker	To investigate the utility of a TransDot test at month 2 and month 6 as a marker of treatment response.	3 years
Secondary	Identification of additional host marker signatures	To identify additional host marker signatures that can be utilized for future improvement of diagnostic tests in the TransDot format or other point-of care tests that might become available in the future	3 years
Secondary	Evaluation of the serum signature's underlying biological processes	To evaluate the biological processes (cell-based immune profile and components) underlying the six-marker serum signature model during TB disease and treatment response. In parallel, the peripheral profile will compare this to the corresponding profile at the lung infection site.	3 years
Secondary	Optimisation of ultra-sensitive TB culture techniques	To refine and optimise ultra-sensitive TB culture techniques on sputum and compare these to standard techniques and the TransDot test results, at baseline and month 6.	3 years
Secondary	Biomarker Biorepository Samples	To collect appropriate additional host samples for future biomarker research	3 years